Project/Area Number |
25462783
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Pediatric surgery
|
Research Institution | National Center for Child Health and Development |
Principal Investigator |
FUCHIMOTO YASUSHI 国立研究開発法人国立成育医療研究センター, その他部局等, その他 (40219077)
|
Co-Investigator(Kenkyū-buntansha) |
KURODA Tatsuo 慶應義塾大学, 医学部, 教授 (60170130)
Ohkita Hajime 慶應義塾大学, 医学部, 准教授 (50317260)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 小児固形腫瘍 / 腫瘍幹細胞 / CD44v / CD13 / 肝芽腫 / 横紋筋肉腫 / CD44v / CD13 / 癌幹細胞 / CD44V / 標的治療 |
Outline of Final Research Achievements |
In hepatoblastomas cell line, rhabdomyosarcoma cell line, neuroblastoma cell line, rhabdoid tumor cell line, the expression of tumor stem cells markers such as CD44 was confirmed with all tumor cell lines, and the expression of CD133 was confirmed with a rhabdomyosarcoma cell lines and the neuroblastoma cell lines, but CD44v was only a few expression in many childhood tumor. Because expression of CD13 was found in approximately 10% in FACS with the hepatoblastomas cell lines (HuH6), we performed sorting of CD13 positive cells and transplanted enrich them in immunodeficiency mice. Tumor was not formed for neither enrich of cell count 1/10,1/100, 1/1000 in 16 weeks.
|